Mayo Clinic Enters Collaboration With Lucence to Expand Global Cancer Testing Access

Mayo Clinic and Lucence have entered a collaboration to expand international access to cancer testing services and improve patient outcomes, according to a news release from the Mayo Clinic.¹ Lucence is a precision oncology company with laboratories located in California and Singapore.

Through this collaboration, Lucence will provide access to its next-generation sequencing liquid biopsy, LiquidHALLMARK, through Mayo Clinic Laboratories. This technology detects clinically relevant biomarkers by analyzing circulating tumor DNA (ctDNA) and ctRNA through blood tests.¹ LiquidHALLMARK profiles ctDNA mutations in 80 genes, including those typically associated with hematologic malignancies such as IDH1, IDH2, KRAS, FLT3, and TP53.² The assay also has a 0.1% limit of detection for single-nucleotide variants and insertion-deletion mutations, according to Lucence’s website.³

“Lucence has developed a novel technology, and this will enable us to make that testing more available to patients,” William Morice, MD, PhD, President and Chief Executive Officer of Mayo Clinic Laboratories, told Blood Cancers Today in an interview. “Lucence allows you to look for both DNA and RNA in the peripheral blood. Prior to this, the other liquid biopsies have a blind spot into an important area of genomic testing and cancer. That’s one of the reasons why we’re excited to be working with Lucence on this technology.”

Test reports include graphical maps to understand cancer genomic profiles and track tumor changes over time, helping clinicians make informed decisions regarding patient diagnosis and therapy.¹

“Combining Lucence’s liquid biopsy testing with Mayo Clinic Laboratories’ broad reach and expertise means that healthcare providers everywhere can be empowered with important information to improve personalized cancer care,” said Min-Han, MBBS, FRCP, PhD, founding CEO and medical director of Lucence, in the news release.

References

1. Mayo Clinic Laboratories and Lucence announce strategic collaboration to enhance cancer testing services. Suzanne Ferguson. January 10, 2025. Accessed February 7, 2025. https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-laboratories-and-lucence-announce-strategic-collaboration-to-enhance-cancer-testing-services/
2. LiquidHALLMARK® ctDNA and ctRNA targets list. Lucence. Accessed February 7, 2024. https://www.lucence.com/liquidhallmark-gene-list/
3. A swift, simple and sensitive blood test for personalized cancer care. Lucence. Accessed February 7, 2024. https://www.lucence.com/liquid-biopsy/